Leonard Zehr – BioTuesdays

This Week's Feature

PDS Biotech to report preliminary data from 3 Phase 2 oncology trials in 2021

PDS Biotechnology (NASDAQ: PDSB) expects to report preliminary data in the first or second quarter of 2021 from a collaboration with the NCI, evaluating its lead oncology product, PDS0101, for the treatment of advanced...

January 19, 2021

Features

Tarsus Pharma developing first treatment for Demodex blepharitis, an ocular condition

Tarsus Pharmaceuticals (NASDAQ:TARS) launched the Phase 2b/3 Saturn-1 clinical trial in September 2020 with its lead asset, TP-03, as the potential first therapeutic for Demodex blepharitis, where eyelids become red...

January 12, 2021

Features

Sernova in clinical development for functional cure of Type 1 Insulin-dependent diabetes

Sernova’s (TSXV:SVA; OTCQB:SEOVF) Cell Pouch System, composed of an implantable device, therapeutic cells and immune protection technologies, has the potential to be a “functional cure” for millions of people with Type...

January 5, 2021

Features

Plus Therapeutics targeting potent radiotherapy directly against glioblastoma

Plus Therapeutics (NASDAQ:PSTV) is developing its lead asset, rhenium nanoliposome (RNL), a targeted and potentially more potent radionucleotide therapy, for the treatment of recurrent glioblastoma and several other...

December 8, 2020

Features

Genelux advancing oncolytic vaccinia virus into pivotal ovarian cancer trial in 2021

Closely-held Genelux expects to arrange an end-of-Phase 2 meeting with the FDA in the first quarter of 2021 and then launch a Phase 3 trial in mid-year with its Olvi-Vec vaccinia virus in combination with chemotherapy...

December 1, 2020

Features

Kintara Therapeutics readies two late-stage cancer drug candidates

Saiid Zarrabian, President and CEO Kintara Therapeutics (NASDAQ:KTRA), fresh off a merger and $25-million private placement, is moving into a global registration trial in newly-diagnosed and recurrent glioblastoma...

November 17, 2020

Features

Hepion Pharmaceuticals employing artificial intelligence to tackle NASH

After close to three decades developing its artificial intelligence platform, Hepion Pharmaceuticals (NASDAQ:HEPA) is deploying its AI-POWR machine learning platform in its clinical program to tackle non-alcoholic...

November 10, 2020

Features

9 Meters Biopharma targeting rare and unmet needs in GI disorders

9 Meters Biopharma (NASDAQ: NMTR) expects to report clinical trial data readouts in 2021 from two gastrointestinal disorders: short bowel syndrome, an underserved and debilitating rare disease, and celiac disease, an...

October 27, 2020

Features

Monopar Therapeutics readies two key clinical trials in fourth quarter

Monopar Therapeutics (NASDAQ:MNPR), which focuses on developing cancer therapies and treatments for cancer-related adverse events, is on track for two important clinical trials with its lead drug candidates, Validive...

October 6, 2020

Features

aTyr Pharma gearing for data readouts in COVID-19, interstitial lung disease

aTyr Pharma (NASDAQ:LIFE) expects to report before the end of 2020 results of a Phase 2 study with its ATYR1923 drug candidate in COVID-19-related severe respiratory complications. It also has a data readout planned in...

September 29, 2020

Author - Leonard Zehr

PDS Biotech to report preliminary data from 3 Phase 2 oncology trials in 2021

Tarsus Pharma developing first treatment for Demodex blepharitis, an ocular condition

Sernova in clinical development for functional cure of Type 1 Insulin-dependent diabetes

Plus Therapeutics targeting potent radiotherapy directly against glioblastoma

Genelux advancing oncolytic vaccinia virus into pivotal ovarian cancer trial in 2021

Kintara Therapeutics readies two late-stage cancer drug candidates

Hepion Pharmaceuticals employing artificial intelligence to tackle NASH

9 Meters Biopharma targeting rare and unmet needs in GI disorders

Monopar Therapeutics readies two key clinical trials in fourth quarter

aTyr Pharma gearing for data readouts in COVID-19, interstitial lung disease

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter